INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 128 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,223 | -81.9% | 167,669 | -79.2% | 0.00% | – |
| Q2 2023 | $360,055 | -59.0% | 806,013 | -24.8% | 0.00% | – |
| Q1 2023 | $878,665 | -40.2% | 1,071,543 | +13.7% | 0.00% | – |
| Q4 2022 | $1,470,194 | -41.2% | 942,432 | -34.9% | 0.00% | – |
| Q3 2022 | $2,501,000 | -0.6% | 1,448,630 | -0.3% | 0.00% | – |
| Q2 2022 | $2,515,000 | -68.2% | 1,453,285 | -34.0% | 0.00% | -100.0% |
| Q1 2022 | $7,900,000 | -76.8% | 2,200,394 | -67.7% | 0.00% | 0.0% |
| Q4 2021 | $33,988,000 | +20.5% | 6,811,212 | +72.9% | 0.00% | -75.0% |
| Q3 2021 | $28,201,000 | -15.4% | 3,938,739 | +9.6% | 0.00% | -20.0% |
| Q2 2021 | $33,319,000 | +19.5% | 3,594,346 | +19.7% | 0.01% | +25.0% |
| Q1 2021 | $27,871,000 | -64.3% | 3,003,438 | -65.9% | 0.00% | -33.3% |
| Q4 2020 | $77,978,000 | +53.4% | 8,811,000 | +101.0% | 0.01% | -40.0% |
| Q3 2020 | $50,839,000 | -62.3% | 4,382,667 | -12.4% | 0.01% | -69.7% |
| Q2 2020 | $134,873,000 | +538.9% | 5,004,541 | +76.4% | 0.03% | +371.4% |
| Q1 2020 | $21,109,000 | +6538.1% | 2,837,220 | +2849.3% | 0.01% | – |
| Q4 2019 | $318,000 | +189.1% | 96,200 | +80.4% | 0.00% | – |
| Q3 2019 | $110,000 | -89.9% | 53,336 | -85.6% | 0.00% | – |
| Q2 2019 | $1,088,000 | +385.7% | 369,524 | +516.9% | 0.00% | – |
| Q1 2019 | $224,000 | -43.0% | 59,900 | -39.0% | 0.00% | – |
| Q4 2018 | $393,000 | -52.7% | 98,254 | -34.2% | 0.00% | – |
| Q3 2018 | $830,000 | +8.5% | 149,291 | -23.5% | 0.00% | – |
| Q2 2018 | $765,000 | +45.2% | 195,277 | +74.5% | 0.00% | – |
| Q1 2018 | $527,000 | -35.3% | 111,900 | -43.2% | 0.00% | – |
| Q4 2017 | $814,000 | -51.7% | 197,107 | -25.8% | 0.00% | – |
| Q3 2017 | $1,685,000 | -42.5% | 265,718 | -28.9% | 0.00% | -100.0% |
| Q2 2017 | $2,928,000 | +111.7% | 373,500 | +78.9% | 0.00% | – |
| Q1 2017 | $1,383,000 | -69.1% | 208,800 | -67.7% | 0.00% | -100.0% |
| Q4 2016 | $4,481,000 | -44.5% | 645,708 | -25.4% | 0.00% | -33.3% |
| Q3 2016 | $8,070,000 | +7.5% | 865,901 | +6.5% | 0.00% | -25.0% |
| Q2 2016 | $7,510,000 | +28.9% | 812,844 | +21.5% | 0.00% | +33.3% |
| Q1 2016 | $5,827,000 | +35.5% | 669,006 | +4.5% | 0.00% | +50.0% |
| Q4 2015 | $4,301,000 | -10.5% | 640,015 | -23.0% | 0.00% | -33.3% |
| Q3 2015 | $4,807,000 | -59.2% | 831,516 | -42.4% | 0.00% | -40.0% |
| Q2 2015 | $11,781,000 | +334.4% | 1,443,683 | +334.3% | 0.01% | +400.0% |
| Q1 2015 | $2,712,000 | -29.8% | 332,437 | -21.0% | 0.00% | -50.0% |
| Q4 2014 | $3,865,000 | -8.7% | 420,984 | -2.0% | 0.00% | 0.0% |
| Q3 2014 | $4,233,000 | -56.4% | 429,705 | -52.1% | 0.00% | -50.0% |
| Q2 2014 | $9,706,000 | – | 897,968 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |